Monte Rosa Therapeutics (GLUE) Revenue & Revenue Breakdown
Monte Rosa Therapeutics Revenue Highlights
0
Latest Revenue (Q)
$4.70M
Monte Rosa Therapeutics Revenue by Period
Monte Rosa Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Monte Rosa Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $4.70M | 341.26% |
2024-03-31 | $1.06M | -87.84% |
2023-12-31 | $8.75M | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Monte Rosa Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
KYMR | Kymera Therapeutics | $78.59M | $3.74M |
NRIX | Nurix Therapeutics | $76.99M | $12.59M |
FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
GBIO | Generation Bio | $5.90M | $4.09M |
STTK | Shattuck Labs | $1.66M | $1.61M |
LYEL | Lyell Immunopharma | $130.00K | $34.00K |
DSGN | Design Therapeutics | - | - |
GRCL | Gracell Bio | - | - |
NKTX | Nkarta | - | - |
ERAS | Erasca | - | - |
SANA | Sana Bio | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |